Tandem Diabetes Care (TNDM)
(Delayed Data from NSDQ)
$39.82 USD
+0.67 (1.71%)
Updated Jul 3, 2024 01:00 PM ET
After-Market: $39.83 +0.01 (0.03%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth B Momentum D VGM
Tandem Diabetes Care, Inc. (TNDM) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$51.92 | $75.00 | $18.00 | 32.62% |
Price Target
Based on short-term price targets offered by 13 analysts, the average price target for Tandem Diabetes Care, Inc. comes to $51.92. The forecasts range from a low of $18.00 to a high of $75.00. The average price target represents an increase of 32.62% from the last closing price of $39.15.
Analyst Price Targets (13)
Broker Rating
Tandem Diabetes Care, Inc. currently has an average brokerage recommendation (ABR) of 1.50 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 14 brokerage firms. The current ABR compares to an ABR of 1.50 a month ago based on 14 recommendations.
Of the 14 recommendations deriving the current ABR, 11 are Strong Buy, representing 78.57% of all recommendations. A month ago, Strong Buy represented 78.57%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/TNDM.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 11 | 11 | 11 | 9 | 8 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 2 | 2 | 2 | 3 | 5 |
Sell | 1 | 1 | 1 | 1 | 1 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.50 | 1.50 | 1.50 | 1.69 | 1.93 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
6/10/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
5/30/2024 | Atlantic Equities | Issie Kirby | Not Available | Strong Buy |
5/22/2024 | Not Identified | Not Identified | Hold | Strong Buy |
5/22/2024 | Lake Street Capital Markets | Brooks G O'Neil | Strong Buy | Strong Buy |
5/6/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
5/3/2024 | Robert W. Baird & Co. | Jeffrey D Johnson | Hold | Hold |
5/3/2024 | Piper Sandler | Matthew O'Brien | Strong Buy | Strong Buy |
5/2/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
4/29/2024 | Wells Fargo Securities | Lawrence H Biegelsen | Hold | Strong Buy |
4/25/2024 | SVB Securities | Michael Kratky | Hold | Strong Buy |
4/1/2024 | Cowen & Co. | Joshua T Jennings | Strong Buy | Strong Buy |
3/26/2024 | Not Identified | Not Identified | Hold | Strong Buy |
2/21/2024 | Raymond James | Jayson T Bedford | Hold | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.50 |
ABR (Last week) | 1.50 |
# of Recs in ABR | 14 |
Average Target Price | $51.92 |
LT Growth Rate | NA |
Industry | Medical - Instruments |
Industry Rank by ABR | 155 of 252 |
Current Quarter EPS Est: | -0.54 |